Yuto Tsubonuma
Overview
Explore the profile of Yuto Tsubonuma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsubonuma Y, Nagata Y, Higashijima K, Minato A, Tomisaki I, Fujimoto N
Cureus
. 2025 Feb;
17(1):e77948.
PMID: 39996187
Recently, enfortumab vedotin has emerged as a promising treatment option for metastatic urothelial carcinoma. Although it does not require dosage adjustments in patients with renal failure, its safety and efficacy,...
2.
Tsubonuma Y, Funakoshi K, Takaba T, Jyojima K, Minato A, Tomisaki I, et al.
J UOEH
. 2024 Mar;
46(1):23-28.
PMID: 38479871
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in...
3.
Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, et al.
Anticancer Res
. 2023 Aug;
43(9):3841-3847.
PMID: 37648316
Neuroendocrine prostate cancer (NEPC) is generally an aggressive form of prostate cancer that can arise de novo or develop as a castration-resistant mechanism. While first-line platinum-based chemotherapy is effective against...